# Nkarta to Participate in November Investor Conferences

October 30, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month:

**Stifel 2025 Healthcare Conference**
November 12, 2025
10:40 a.m. ET – fireside chat

**TD Cowen's Immunology & Inflammation Summit**
November 13, 2025
5 p.m. ET – fireside chat

A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

**About Nkarta**
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at www.nkartatx.com.

**Nkarta Media/Investor Contact:**
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com